| Savita R Kurup, MD | |
|
14131 Midway Road, Suite 620, Addison, TX 75001-3623 | |
| (972) 249-0200 | |
| (972) 249-0206 |
| Full Name | Savita R Kurup |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 37 Years |
| Location | 14131 Midway Road, Addison, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568457968 | NPI | - | NPPES |
| 080463501 | Medicaid | TX | |
| 146729201 | Medicaid | TX | |
| 146729202 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L2394 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asana Hospice | Fort worth, TX | Hospice |
| Texas Health Harris Methodist Hospital Southwest F | Fort worth, TX | Hospital |
| Texas Health Harris Methodist Hospital Fort Worth | Fort worth, TX | Hospital |
| Colonial Manor Nursing Center | Cleburne, TX | Nursing home |
| Wedgewood Nursing Home | Fort worth, TX | Nursing home |
| Advanced Rehabilitation & Healthcare Of Burleson | Burleson, TX | Nursing home |
| Entity Name | Texas Health Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174573596 PECOS PAC ID: 4385535954 Enrollment ID: O20040323000759 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | Apogee Medical Group Texas Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558318071 PECOS PAC ID: 9436151792 Enrollment ID: O20070215000533 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629307095 PECOS PAC ID: 3476688318 Enrollment ID: O20100317001021 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | Hospital Medicine Associates Of Tx Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538520218 PECOS PAC ID: 4587962949 Enrollment ID: O20160419000296 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | Apptexashm Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700399078 PECOS PAC ID: 9335406677 Enrollment ID: O20171122000562 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | La Magna Health Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699285346 PECOS PAC ID: 0749540045 Enrollment ID: O20180206001403 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | M Medical Group Se Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609530013 PECOS PAC ID: 4385037670 Enrollment ID: O20221216001760 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Entity Name | Lake Granbury Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043992001 PECOS PAC ID: 6204280779 Enrollment ID: O20231003000017 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Savita R Kurup, MD 14131 Midway Road, Suite 620, Addison, TX 75001-3623 Ph: (972) 249-0200 | Savita R Kurup, MD 14131 Midway Road, Suite 620, Addison, TX 75001-3623 Ph: (972) 249-0200 |
News Archive
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.
Gelesis, Inc., a biotechnology company developing a novel category of therapies to safely induce weight loss, improve glycemic control, and treat other chronic diseases related to the gastrointestinal (GI) pathway, is pleased to report today that the last patient has completed treatment in the pivotal GLOW (Gelesis Loss Of Weight) Study.
Qardio, a technology company dedicated to transforming the way we manage our heart health and track our wellness, is formally announcing the launch of the QardioArm at the 2014 CES show. QardioArm is a revolutionary blood pressure monitor.
Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.
› Verified 1 days ago
Crisanto G Dimafelix, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 15810 Midway Road, Addison, TX 75001 Phone: 972-458-8111 Fax: 972-458-7776 | |
Heather Hughes, FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15301 Spectrum Dr Ste 330, Addison, TX 75001 Phone: 972-661-2273 | |
Dr. Yeshodra Sagar, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14131 Midway Rd, Suite 620, Addison, TX 75001 Phone: 972-249-0200 Fax: 972-249-0206 | |
Christine Ijeoma Nwabeke, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 15250 Quorum Dr Apt 410, Addison, TX 75001 Phone: 281-639-2849 | |
Nadia Nisar Siddiqui, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14131 Midway Rd, Suite 620, Addison, TX 75001 Phone: 972-249-0200 Fax: 972-249-0206 | |
Majdouleen Michil Georgeos, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15810 Midway Rd, Addison, TX 75001 Phone: 972-458-8111 | |
Dr. Robert Contreras, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 15810 Midway Rd, Addison, TX 75001 Phone: 972-458-8111 Fax: 972-458-7776 |